Edap Tms SA (NASDAQ:EDAP) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price target of $6.50 for the company and are predicting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 90 out of 255 based on the ratings given to related companies.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Edap Tms from a “hold” rating to a “strong-buy” rating and set a $5.50 price target on the stock in a research report on Tuesday, April 9th. ValuEngine raised shares of Edap Tms from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price target on shares of Edap Tms in a research report on Wednesday, April 3rd. Finally, TheStreet raised shares of Edap Tms from a “d+” rating to a “c-” rating in a research report on Thursday, February 14th.
EDAP stock opened at $5.13 on Wednesday. The company has a market cap of $152.52 million, a PE ratio of 256.50 and a beta of 1.60. Edap Tms has a one year low of $1.35 and a one year high of $5.42.
Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Monday, April 1st. The medical equipment provider reported $0.04 EPS for the quarter. The firm had revenue of $15.11 million for the quarter, compared to analyst estimates of $11.74 million. Edap Tms had a negative net margin of 0.93% and a positive return on equity of 3.77%. As a group, analysts forecast that Edap Tms will post 0.11 earnings per share for the current year.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Recommended Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.